<DOC>
	<DOCNO>NCT01263808</DOCNO>
	<brief_summary>This study compare cardiac safety inhale indacaterol placebo oral moxifloxacin .</brief_summary>
	<brief_title>Cardiac Safety Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy , nonsmoking Body mass index ( BMI ) 18.532 kg/m2 Body weight least 50 kg Recent/concurrent use concomitant medication ( except acetaminophen ) Recent participation clinical trial Recent donation loss blood History/presence range medical condition , include electrocardiographic ( ECG ) abnormality , diabetes mellitus , hyperthyroidism impair renal function Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>Moxifloxacin</keyword>
</DOC>